1.The complications of induction chemotherapy in adult patients with acute myelogenous leukemia at Hue Central Hospital
Journal of Medical Research 2007;51(4):13-19
Background: Acute myelogenous leukemia (AML) is the most common disease of malignant hemopathy in adult. Although induction therapy induced the long complete remissions, but complications of this intensive therapy is very serious. Objectives: to evaluate the complications of induction chemotherapy in adult patients with acute myelogenous leukemia at Hue central hospital". Subject and method: 30 AML patients aged from 10 to 30 were treated at clinical hematology service, Hue central hospital from Mars, 2005 to July, 2006. The diagnosis of AML based on FAB classification. Induction therapy consisted of a combination of cytarabin 100mglm2/day given by continuous IV over 7 days and daunorubicin 45mg/m2/day for 3 days. Complications were evaluated based on toxicity grade of WHO. \r\n', u'Results: Alopecia was the most common complications (100%) but good recovery. Gastrointestinal toxicity included: nausea and vomiting (6.6%), oral mucositis (40%) and diarrhea (30%) Cerebral hemorrhage due thrombocytopenia (6.66%) and neutropenic septicemia (20%) are the most severe complications. Acute complications on cardio - vascular system were rare and only mild degree. Conclusion: The complications of induction chemotherapy in adult patients with acute myelogenous leukemia occur at many organs with different degrees. Among of them, bone marrow suppression is the most severe complication with cerebral hemorrhage due thrombocytopenia and neutropenic septicemia which are fatal complications in theses patients. \r\n', u'\r\n', u'
Leukemia
;
Myeloid
;
Acute/ complications
;
pathology
;
drug therapy
4.Study complication of aplastic anemia following chemotherapy of acute myelogenous leukemia
Journal of Medical Research 2007;51(4):9-13
Background: Aplastic anemia following chemotherapy of acute leukemia is a common complication, which may lead to severe consequences. Objective: To study characteristics of aplastic anemia occurred in ccute myelogenous leukemia (AML) patients, following chemotherapy. Subjects and methods: A prospective study was carried out in 50 AML patients treated at National Institute of Hematology and Blood Transfusion from Aug 2005 to Dec 2006. These patients were treated by induction chemotherapy with "3+7" regime. Result: Aplastic anemia had been seen in 100% patients. Characteristics of this condition were poor marrow cells (average marrow cell count was 15.1\xb112.6 G/l) and strongly decreased counts of hemoglobin, white blood cells and platelets. Hemoglobin, white blood cell and platelet counts at the lowest level were 83.32 g/l; 0.96 G/l; 30.18 G/l; respectively. This situation prolonged for 3-4 weeks and changed into the most severe condition at the end of second week after chemotherapy. Infection frequency was 92%. Conclusion: Aplastic anemia following chemotherapy of AML patients is a common complication with severe consequences such as significant decrease of WBC and platelet counts, which may lead to opportunistic infection. Hence, this complication must be monitored, detected and treated promptly. \r\n', u'\r\n', u'
Leukemia
;
Myeloid
;
Acute/ pathology
;
prevention &
;
control
;
complications
;
drug therapy
;
Anemia
;
Aplastic/ blood
;
complications
;
pathology
5.Acute Lymphoblastic Leukemia Associated with Brucellosis in Two Patients with Fever and Pancytopenia.
Bulent ESER ; Fevzi ALTUNTAS ; Isin SOYUER ; Ozlem ER ; Ozlem CANOZ ; Hasan Senol COSKUN ; Mustafa CETIN ; Ali UNAL
Yonsei Medical Journal 2006;47(5):741-744
Brucellosis is a disease involving the lymphoproliferative system, which may lead to changes in the hematological parameters; however, pancytopenia is a rare finding. However, malignant diseases in association with brucellosis are rarely the cause of pancytopenia. Herein, two cases with fever and pancytopenia, diagnosed as simultaneous acute lymphoblastic leukemia and brucellosis are presented. Anti-leukemic therapy and brucellosis treatment were administered simultaneously, and normal blood parameters obtained. The first patient is in complete remission; the other recovered from the brucellosis, but later died due to a leukemic relapse.
Pancytopenia/diagnosis/*etiology/therapy
;
Leukemia, Lymphocytic, Acute/*complications/pathology/therapy
;
Humans
;
Fever
;
Female
;
Brucellosis/*complications/diagnosis/therapy
;
Adult
6.Five cases of cytomegalovirus infection detected by in situ hybridization and antigenemia assay.
Jin Hong YOO ; Jong Young CHOI ; Yang Ree KIM ; Yeong Jin CHOI ; Sang In SHIM ; Hak Ki KIM ; Chul Woo YANG ; Yong Soo KIM ; Chi Wha HAHN ; Wan Shik SHIN ; Chong Won PARK ; Moon Won KANG ; Choon Choo KIM ; Byung Kee BANG ; Dong Jip KIM
Journal of Korean Medical Science 1994;9(6):507-512
We report five cases of cytomegalovirus infection in immunocompromised patients which were detected by either cytomegalovirus antigenemia assay or in situ hybridization. Four cases had leukemia and the other had chronic renal failure. All the three BMT recipients suffered from GvHD. Interestingly, there was an unique case of CMV disease without a history of BMT, which reminded us that CMV could attack immunocompromised patients who had not undergone transplantation, too. Four out of five cases died. We think that cytomegalovirus infection or disease should not be regarded as a minor problem in post-transplantation infection in Korea.
Adolescent
;
Adult
;
Antigens, Viral/*blood
;
*Bone Marrow Transplantation
;
Case Report
;
Cytomegalovirus/*immunology
;
Cytomegalovirus Infections/complications/*diagnosis
;
Fatal Outcome
;
Graft vs Host Disease/complications
;
Human
;
Immunocompromised Host
;
In Situ Hybridization
;
Kidney Failure, Chronic/complications
;
Kidney Transplantation
;
Leukemia/*complications/therapy
;
Leukemia, Lymphocytic, Acute, L2/complications/therapy
;
Leukemia, Myelocytic, Acute/complications/therapy
;
Leukemia, Myeloid, Chronic/complications/therapy
;
Male
;
Viremia/*diagnosis
9.Clinical experience in diagnosis and treatment of acute hybrid leukemia.
Yuan LI ; Jiang-Chao QIAN ; Hai-Xia ZHOU ; Ju-xiang WANG
Chinese Journal of Pediatrics 2004;42(7):515-515
Acute Disease
;
Anemia
;
etiology
;
Child
;
Fever
;
etiology
;
Humans
;
Leukemia
;
complications
;
diagnosis
;
therapy
;
Male
;
Patient Care
;
Prognosis
10.Treatment of acute leukemia complicated by invasive aspergillosis in children.
Ying LIU ; Suo-Qin TANG ; Jian-Wen WANG ; Hui LONG ; Chen FENG ; Hao ZHANG
Chinese Journal of Contemporary Pediatrics 2009;11(11):901-904
OBJECTIVETo study the antifungal treatment and intensive chemotherapy in children with acute leukemia and invasive aspergillosis.
METHODSThe diagnosis and treatment of 4 cases of childhood acute leukemia complicated by invasive aspergillosis between July 2007 and July 2008 were studied retrospectively.
RESULTSThree children who underwent remission induction chemotherapy for ALL and one who underwent consolidation chemotherapy for AML developed invasive aspergillosis. One child with proven aspergillosis and 3 with possible aspergillosis all had halo sign on CT at diagnosis. Voriconazole or amphotericin B was given as primary therapy. Improvements of fungal lesions were shown by CT after two to four weeks of antifungal therapy. Complete radiologic remissions were achieved between 4 months and one year. The intensive chemotherapy schedule was continued in all of 4 cases. The median time from fungal infection to the continuation of chemotherapy was 35 days. None showed recurrence of fungal infection.
CONCLUSIONSThe halo sign on CT may be a reliable indicator for the early diagnosis of invasive aspergillosis. The preemptive antifungal therapy on the basis of the identification of a halo sign and the reversal of immunosuppression may improve the outcome of invasive aspergillosis. Prolonged antifungal treatment during subsequent cycles of chemotherapy permits completion of scheduled intensive chemotherapy without fungal recurrence.
Antifungal Agents ; therapeutic use ; Aspergillosis ; drug therapy ; Child ; Child, Preschool ; Female ; Humans ; Leukemia, Myeloid, Acute ; complications ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; complications